The drug, lecanemab, was approved by the FDA this summer. The UW study focuses on patients without symptoms who have early ...

The FDA confirmed ... with Alzheimer’s get their health coverage through Medicare. And private insurers have followed its lead by withholding coverage for Leqembi and a similar drug, Aduhelm ...

Joe Biden has made it less likely that we’ll find a cure for Alzheimer’s any time ... on drugs that don’t get that far is by making a substantial profit on the drugs the FDA approves.

For the first time, people worried about their risk of Alzheimer’s disease can go online, order a blood test, and receive results in the privacy of their homes. This might seem appealing on the ...

According to the FDA, the drug does come with possible ... mother and aunt both developed Alzheimer's in 2008. "I just thought it would be a good idea to get involved," he said.

The early data released to the Alzheimer’s research community ... to champion the drug and help it get to the decision table. There is no way to know if any kind of FDA championing could have ...

There's a new weight loss drug that has been given FDA approval. Dr. Mike Cirigliano ... Increase Tenfold How to speak to someone with dementia The hostages' families should have been jailed ...

The European Medicine Agency's committee backed Krazati following a re-examination ... Krazati returned to spotlight last month after the U.S. FDA's advisers declined to back a rival drug, Amgen's ...

The European Medicine Agency's committee backed Krazati following ... to spotlight last month after the U.S. FDA's advisers declined to back a rival drug, Amgen's Lumakras, for a traditional ...

Last week, a congressional report found that FDA's approval of a similar Alzheimer's drug called Aduhelm ... “For me, the minute that drug comes on the market — and I get my doctor ...

It's called the AHEAD Study and they are looking at the FDA-approved drug Leqembi, which is already approved for people with significant dementia ... it's also important to get a diverse group ...

The European Medicine Agency's committee backed Krazati following ... to spotlight last month after the U.S. FDA's advisers declined to back a rival drug, Amgen's Lumakras, for a traditional ...